Watching Vertex Pharmaceuticals; Shares Trading Lower, FDA Label Update For ALYFTREK Adds Neuropsychiatric Risk Warning And Intracranial Hypertension, Alongside Strengthened Liver Safety Monitoring

Vertex Pharmaceuticals' shares are trading lower following a recent FDA update for its drug ALYFTREK, which now includes warnings about neuropsychiatric risks and intracranial hypertension. Additionally, the update has strengthened liver safety monitoring protocols. The market reaction reflects investor concerns regarding these new safety warnings.